April 30, 2019 08:48 AM EDTUpdated May 28, 11:44 AM
R&D

As Eli Lil­ly suf­fers a sharp set­back on rev­enue pro­jec­tions, the on­col­o­gy group qui­et­ly ex­e­cutes 2 of its top mid-stage drugs

John Carroll

Editor & Founder

Eli Lil­ly took a hit Tues­day morn­ing as the phar­ma gi­ant re­vealed just how painful the with­draw­al of Lartru­vo will be for its on­col­o­gy …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

A service from the Financial Times